drugset / Trial / NCT04232332
The Phase I Study of Recombinant Human Nerve Growth Factor Injection
RandomizedSequentialTriple-blindTreatment
Summary
A randomized, double-blind, placebo-controlled, single/multiple dose study of recombinant human nerve growth factor injection in healthy Chinese volunteers on safety, tolerability and pharmacokinetics
Timeline
- Start
- 2019-12-26
- Primary completion
- 2021-12-31
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rhNGF | Protein / enzyme biologic | 3.75 ug | Intramuscular |
| Subject | rhNGF | Protein / enzyme biologic | 7.5 ug | Intramuscular |